Vertex Pharmaceuticals Stock Performance
| VRTX Stock | USD 453.36 0.38 0.08% |
On a scale of 0 to 100, Vertex Pharmaceuticals holds a performance score of 10. The entity has a beta of 0.85, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vertex Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Vertex Pharmaceuticals is expected to be smaller as well. Please check Vertex Pharmaceuticals' value at risk, kurtosis, price action indicator, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Vertex Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vertex Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting basic indicators, Vertex Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.08) | Five Day Return (2.01) | Year To Date Return 11.73 | Ten Year Return 260.3 | All Time Return 10 K |
Last Split Factor 2:1 | Last Split Date 2000-08-24 |
1 | Why Vertex Pharmaceuticals is a Top Momentum Stock for the Long-Term | 12/08/2025 |
2 | Google Says Its New Gemini 3 Flash AI Model Is Better and Faster Than 2.5 Pro | 12/17/2025 |
3 | Palo Alto Networks, Google Cloud partner to enhance AI and cloud security | 12/22/2025 |
4 | Vertex Pharmaceuticals Incorporated Is a Trending Stock Facts to Know Before Betting on It | 12/23/2025 |
5 | Vertex Minerals Secures 4.5 Million in Loan Facilities for Reward Gold Mine | 12/24/2025 |
6 | Should You Be Confident in Vertex Pharmaceuticals Incorporateds Long-Term Outlook | 12/29/2025 |
| Begin Period Cash Flow | 10.4 B | |
| Total Cashflows From Investing Activities | -3.8 B |
Vertex Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 40,330 in Vertex Pharmaceuticals on October 3, 2025 and sell it today you would earn a total of 5,006 from holding Vertex Pharmaceuticals or generate 12.41% return on investment over 90 days. Vertex Pharmaceuticals is currently generating 0.2003% in daily expected returns and assumes 1.5317% risk (volatility on return distribution) over the 90 days horizon. In different words, 13% of stocks are less volatile than Vertex, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vertex Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vertex Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vertex Pharmaceuticals, and traders can use it to determine the average amount a Vertex Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1308
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VRTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Vertex Pharmaceuticals is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vertex Pharmaceuticals by adding it to a well-diversified portfolio.
Vertex Pharmaceuticals Fundamentals Growth
Vertex Stock prices reflect investors' perceptions of the future prospects and financial health of Vertex Pharmaceuticals, and Vertex Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vertex Stock performance.
| Return On Equity | 0.22 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.31 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 112.2 B | ||||
| Shares Outstanding | 253.72 M | ||||
| Price To Earning | 24.57 X | ||||
| Price To Book | 6.74 X | ||||
| Price To Sales | 9.92 X | ||||
| Revenue | 11.02 B | ||||
| Gross Profit | 6.18 B | ||||
| EBITDA | 486.3 M | ||||
| Net Income | (535.6 M) | ||||
| Cash And Equivalents | 9.77 B | ||||
| Cash Per Share | 38.06 X | ||||
| Total Debt | 1.75 B | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.70 X | ||||
| Book Value Per Share | 68.20 X | ||||
| Cash Flow From Operations | (492.6 M) | ||||
| Earnings Per Share | 14.20 X | ||||
| Market Capitalization | 116.33 B | ||||
| Total Asset | 22.53 B | ||||
| Retained Earnings | 9.61 B | ||||
| Working Capital | 6.03 B | ||||
| Current Asset | 1.41 B | ||||
| Current Liabilities | 506.35 M | ||||
About Vertex Pharmaceuticals Performance
Evaluating Vertex Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Vertex Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vertex Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 287.47 | 301.84 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | (0.03) | (0.03) |
Things to note about Vertex Pharmaceuticals performance evaluation
Checking the ongoing alerts about Vertex Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vertex Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 11.02 B. Net Loss for the year was (535.6 M) with profit before overhead, payroll, taxes, and interest of 6.18 B. | |
| Vertex Pharmaceuticals currently holds about 9.77 B in cash with (492.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 38.06. | |
| Vertex Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 97.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from insidermonkey.com: Should You Be Confident in Vertex Pharmaceuticals Incorporateds Long-Term Outlook |
- Analyzing Vertex Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vertex Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Vertex Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vertex Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vertex Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vertex Pharmaceuticals' stock. These opinions can provide insight into Vertex Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.